{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T02:22:15Z","timestamp":1791685335750,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institute of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Alberta Prion Research Institute"},{"DOI":"10.13039\/501100000145","name":"Alberta Innovates - Health Solutions","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000145","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["acta neuropathol commun"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Prion diseases are fatal, infectious, and incurable neurodegenerative disorders caused by misfolding of the cellular prion protein (PrP\n                    <jats:sup>C<\/jats:sup>\n                    ) into the infectious isoform (PrP\n                    <jats:sup>Sc<\/jats:sup>\n                    ). In humans, there are sporadic, genetic and infectious etiologies, with sporadic Creutzfeldt-Jakob disease (sCJD) being the most common form. Currently, no treatment is available for prion diseases. Cellular cholesterol is known to impact prion conversion, which in turn results in an accumulation of cholesterol in prion-infected neurons. The major elimination of brain cholesterol is achieved by the brain specific enzyme, cholesterol 24-hydroxylase (CYP46A1). Cyp46A1 converts cholesterol into 24(S)-hydroxycholesterol, a membrane-permeable molecule that exits the brain. We have demonstrated for the first time that Cyp46A1 levels are reduced in the brains of prion-infected mice at advanced disease stage, in prion-infected neuronal cells and in post-mortem brains of sCJD patients. We have employed the Cyp46A1 activator efavirenz (EFV) for treatment of prion-infected neuronal cells and mice. EFV is an FDA approved anti-HIV medication effectively crossing the blood brain barrier and has been used for decades to chronically treat HIV patients. EFV significantly mitigated PrP\n                    <jats:sup>Sc<\/jats:sup>\n                    propagation in prion-infected cells while preserving physiological PrP\n                    <jats:sup>C<\/jats:sup>\n                    and lipid raft integrity. Notably, oral administration of EFV treatment chronically at very low dosage starting weeks to months after intracerebral prion inoculation of mice significantly prolonged the lifespan of animals. In summary, our results suggest that Cyp46A1 as a novel therapeutic target and that its activation through repurposing the anti-retroviral medication EFV might be valuable treatment approach for prion diseases.\n                  <\/jats:p>","DOI":"10.1186\/s40478-021-01162-1","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T12:03:07Z","timestamp":1617278587000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Oral administration of repurposed drug targeting Cyp46A1 increases survival times of prion infected mice"],"prefix":"10.1186","volume":"9","author":[{"given":"Tahir","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Hannaoui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish","family":"Nemani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waqas","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Zemlyankina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pearl","family":"Cherry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su Yeon","family":"Shim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann M.","family":"Schaetzl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5923-3464","authenticated-orcid":false,"given":"Sabine","family":"Gilch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"1162_CR1","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1126\/science.6801762","volume":"216","author":"SB Prusiner","year":"1982","unstructured":"Prusiner SB (1982) Novel proteinaceous infectious particles cause scrapie. Science 216:136\u2013144","journal-title":"Science"},{"key":"1162_CR2","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1172\/JCI22438","volume":"114","author":"A Aguzzi","year":"2004","unstructured":"Aguzzi A, Heikenwalder M, Miele G (2004) Progress and problems in the biology, diagnostics, and therapeutics of prion diseases. J Clin Investig 114:153\u2013160","journal-title":"J Clin Investig"},{"key":"1162_CR3","doi-asserted-by":"publisher","first-page":"e26","DOI":"10.1371\/journal.ppat.0020026","volume":"2","author":"JC Watts","year":"2006","unstructured":"Watts JC, Balachandran A, Westaway D (2006) The expanding universe of prion diseases. PLoS Pathog 2:e26","journal-title":"PLoS Pathog"},{"key":"1162_CR4","doi-asserted-by":"publisher","first-page":"e94020","DOI":"10.1371\/journal.pone.0094020","volume":"9","author":"CC Chen","year":"2014","unstructured":"Chen CC, Wang YH (2014) Estimation of the exposure of the UK population to the bovine spongiform encephalopathy agent through dietary intake during the period 1980 to 1996. PLoS ONE 9:e94020","journal-title":"PLoS ONE"},{"key":"1162_CR5","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1111\/jnc.14877","volume":"152","author":"S Hannaoui","year":"2020","unstructured":"Hannaoui S, Arifin MI, Chang SC et al (2020) Cellulose ether treatment in vivo generates chronic wasting disease prions with reduced protease resistance and delayed disease progression. J Neurochem 152:727\u2013740","journal-title":"J Neurochem"},{"key":"1162_CR6","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1146\/annurev.mi.43.100189.002021","volume":"43","author":"SB Prusiner","year":"1989","unstructured":"Prusiner SB (1989) Scrapie prions. Annu Rev Microbiol 43:345\u2013374","journal-title":"Annu Rev Microbiol"},{"key":"1162_CR7","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/356577a0","volume":"356","author":"H Bueler","year":"1992","unstructured":"Bueler H, Fischer M, Lang Y et al (1992) Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature 356:577\u2013582","journal-title":"Nature"},{"key":"1162_CR8","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/bmb\/66.1.109","volume":"66","author":"B Caughey","year":"2003","unstructured":"Caughey B (2003) Prion protein conversions: insight into mechanisms, TSE transmission barriers and strains. Br Med Bull 66:109\u2013120","journal-title":"Br Med Bull"},{"key":"1162_CR9","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1093\/emboj\/21.5.1031","volume":"21","author":"GS Baron","year":"2002","unstructured":"Baron GS, Wehrly K, Dorward DW, Chesebro B, Caughey B (2002) Conversion of raft associated prion protein to the protease-resistant state requires insertion of PrP-res (PrPSc) into contiguous membranes. EMBO J 21:1031\u20131040","journal-title":"EMBO J"},{"key":"1162_CR10","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1083\/jcb.129.1.121","volume":"129","author":"A Taraboulos","year":"1995","unstructured":"Taraboulos A, Scott M, Semenov A, Avrahami D, Laszlo L, Prusiner SB (1995) Cholesterol depletion and modification of COOH terminal targeting sequence of the prion protein inhibit formation of the scrapie isoform. J Cell Biol 129:121\u2013132","journal-title":"J Cell Biol"},{"key":"1162_CR11","doi-asserted-by":"publisher","first-page":"3979","DOI":"10.1007\/s00018-009-0158-4","volume":"66","author":"S Gilch","year":"2009","unstructured":"Gilch S, Bach C, Lutzny G, Vorberg I, Sch\u00e4tzl HM (2009) Inhibition of cholesterol recycling impairs cellular PrP(Sc) propagation. Cell Mol Life Sci 66:3979\u20133991","journal-title":"Cell Mol Life Sci"},{"key":"1162_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1074\/jbc.M113.535807","volume":"289","author":"HL Cui","year":"2014","unstructured":"Cui HL, Guo B, Scicluna B et al (2014) Prion infection impairs cholesterol metabolism in neuronal cells. J Biol Chem 289:789\u2013802","journal-title":"J Biol Chem"},{"key":"1162_CR13","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.3390\/v6114505","volume":"6","author":"S Hannaoui","year":"2014","unstructured":"Hannaoui S, Shim SY, Cheng YC, Corda E, Gilch S (2014) Cholesterol balance in prion diseases and Alzheimer\u2019s disease. Viruses 6:4505\u20134535","journal-title":"Viruses"},{"key":"1162_CR14","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1194\/jlr.M073718","volume":"58","author":"V Perrier","year":"2017","unstructured":"Perrier V, Imberdis T, Lafon P et al (2017) Plasma cholesterol level determines in vivo prion propagation. J Lipid Res 58:1950\u20131961","journal-title":"J Lipid Res"},{"key":"1162_CR15","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","volume":"24","author":"I Bjorkhem","year":"2004","unstructured":"Bjorkhem I, Meaney S (2004) Brain cholesterol: long secret life behind a barrier. Arterioscler Thromb Vasc Biol 24:806\u2013815","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"1162_CR16","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1242\/dmm.010124","volume":"5","author":"JE Vance","year":"2012","unstructured":"Vance JE (2012) Dysregulation of cholesterol balance in the brain: contribution to neurodegenerative diseases. Dis Models Mech 5:746\u2013755","journal-title":"Dis Models Mech"},{"key":"1162_CR17","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1093\/brain\/awz174","volume":"142","author":"R Kacher","year":"2019","unstructured":"Kacher R, Lamazi\u00e8re A, Heck N et al (2019) CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington\u2019s disease. Brain 142:2432\u20132450","journal-title":"Brain"},{"key":"1162_CR18","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s00401-019-02019-7","volume":"138","author":"C N\u00f3brega","year":"2019","unstructured":"N\u00f3brega C, Mendon\u00e7a L, Marcelo A et al (2019) Restoring brain cholesterol turnover improves autophagy and has therapeutic potential in mouse models of spinocerebellar ataxia. Acta Neuropathol 138:837\u2013858","journal-title":"Acta Neuropathol"},{"key":"1162_CR19","doi-asserted-by":"publisher","first-page":"e48143","DOI":"10.15252\/embr.201948143","volume":"20","author":"DN Mitroi","year":"2019","unstructured":"Mitroi DN, Pereyra-G\u00f3mez G, Soto-Huelin B et al (2019) NPC1 enables cholesterol mobilization during long-term potentiation that can be restored in Niemann-Pick disease type C by CYP46A1 activation. EMBO Rep 20:e48143","journal-title":"EMBO Rep"},{"key":"1162_CR20","doi-asserted-by":"publisher","first-page":"2383","DOI":"10.1093\/brain\/awv166","volume":"138","author":"F Djelti","year":"2015","unstructured":"Djelti F, Braudeau J, Hudry E et al (2015) CYP46A1 inhibition, brain cholesterol accumulation and neurodegeneration pave the way for Alzheimer\u2019s disease. Brain 138:2383\u20132398","journal-title":"Brain"},{"key":"1162_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1007\/s13311-019-00731-6","volume":"16","author":"AM Petrov","year":"2019","unstructured":"Petrov AM, Pikuleva IA (2019) Cholesterol 24-hydroxylation by CYP46A1: benefits of modulation for brain diseases. Neurotherapeutics 16:635\u2013648","journal-title":"Neurotherapeutics"},{"key":"1162_CR22","doi-asserted-by":"publisher","first-page":"11195","DOI":"10.1128\/JVI.02559-06","volume":"81","author":"M Prior","year":"2007","unstructured":"Prior M, Lehmann S, Sy MS, Molloy B, McMahon HE (2007) Cyclodextrins inhibit replication of scrapie prion protein in cell culture. J Virol 81:11195\u201311207","journal-title":"J Virol"},{"key":"1162_CR23","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.mcn.2005.10.008","volume":"31","author":"S Gilch","year":"2006","unstructured":"Gilch S, Kehler C, Sch\u00e4tzl HM (2006) The prion protein requires cholesterol for cell surface localization. Mol Cell Neurosci 31:346\u2013353","journal-title":"Mol Cell Neurosci"},{"key":"1162_CR24","doi-asserted-by":"publisher","first-page":"31260","DOI":"10.1074\/jbc.M109.004382","volume":"284","author":"C Bach","year":"2009","unstructured":"Bach C, Gilch S, Rost R et al (2009) Prion-induced activation of cholesterogenic gene expression by Srebp2 in neuronal cells. J Biol Chem 284:31260\u201331269","journal-title":"J Biol Chem"},{"key":"1162_CR25","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.bbrc.2005.06.060","volume":"334","author":"AR Brown","year":"2006","unstructured":"Brown AR, Rebus S, McKimmie CS, Robertson K, Williams A, Fazakerley JK (2006) Gene expression profiling of the preclinical scrapie-infected hippocampus. Biochem Biophys Res Commun 334:86\u201395","journal-title":"Biochem Biophys Res Commun"},{"key":"1162_CR26","doi-asserted-by":"publisher","first-page":"3869","DOI":"10.1073\/pnas.0600316103","volume":"103","author":"TJ Kotti","year":"2006","unstructured":"Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM, Russell DW (2006) Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc Natl Acad Sci USA 103:3869\u20133874","journal-title":"Proc Natl Acad Sci USA"},{"key":"1162_CR27","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.1016\/S0022-2275(20)32188-X","volume":"39","author":"I Bjorkhem","year":"1998","unstructured":"Bjorkhem I, L\u00fctjohann D, Diczfalusy U, St\u00e5hle L, Ahlborg G, Wahren J (1998) Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 39:1594\u20131600","journal-title":"J Lipid Res"},{"key":"1162_CR28","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1073\/pnas.96.13.7238","volume":"96","author":"EG Lund","year":"1998","unstructured":"Lund EG, Guileyardo JM, Russell DW (1998) cDNA cloning of cholesterol 24-hydroxylase, a mediator of cholesterol homeostasis in the brain. Proc Natl Acad Sci USA 96:7238\u20137243","journal-title":"Proc Natl Acad Sci USA"},{"key":"1162_CR29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/S0022-2275(20)32337-3","volume":"42","author":"S Meaney","year":"2001","unstructured":"Meaney S, Hassan M, Sakinis A et al (2001) Evidence that major oxysterols in human circulation originate from distinct pools of cholesterol: a stable isotope study. J Lipid Res 42:70\u201378","journal-title":"J Lipid Res"},{"key":"1162_CR30","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.freeradbiomed.2015.06.036","volume":"87","author":"N Noguchi","year":"2015","unstructured":"Noguchi N, Urano Y, Takabe W, Saito Y (2015) New aspects of 24(S)-hydroxycholesterol in modulating neuronal cell death. Free Radic Biol Med 87:366\u2013372","journal-title":"Free Radic Biol Med"},{"key":"1162_CR31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/j.1471-4159.2004.02183.x","volume":"88","author":"Y Liang","year":"2004","unstructured":"Liang Y, Lin S, Beyer TP et al (2004) A liver X receptor and retinoid X receptor heterodimer mediates apolipoprotein E expression, secretion and cholesterol homeostasis in astrocytes. J Neurochem 88:623\u2013634","journal-title":"J Neurochem"},{"key":"1162_CR32","doi-asserted-by":"publisher","first-page":"9799","DOI":"10.1073\/pnas.93.18.9799","volume":"93","author":"D Lutjohann","year":"1996","unstructured":"Lutjohann D, Breuer O, Ahlborg G et al (1996) Cholesterol homeostasis in human brain: evidence for an age-dependent flux of 24S-hydroxycholesterol from the brain into the circulation. Proc Natl Acad Sci USA 93:9799\u20139804","journal-title":"Proc Natl Acad Sci USA"},{"key":"1162_CR33","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1194\/jlr.M300164-JLR200","volume":"44","author":"C Xie","year":"2003","unstructured":"Xie C, Lund EG, Turley SD, Russell DW, Dietschy JM (2003) Quantitation of two pathways for cholesterol excretion from the brain in normal mice and mice with neurodegeneration. J Lipid Res 44:1780\u20131789","journal-title":"J Lipid Res"},{"key":"1162_CR34","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3390\/microorganisms8040599","volume":"8","author":"M Stefanik","year":"2020","unstructured":"Stefanik M, Valdes JJ, Ezebuo FC et al (2020) FDA-approved drugs efavirenz, tipranavir, and dasabuvir inhibit replication of multiple flaviviruses in vero cells. Microorganisms 8:599. https:\/\/doi.org\/10.3390\/microorganisms8040599","journal-title":"Microorganisms"},{"key":"1162_CR35","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1517\/17425250903483207","volume":"6","author":"NY Rakhmaninaa","year":"2010","unstructured":"Rakhmaninaa NY, Vanden AJN (2010) Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol 6:95\u2013103","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"1162_CR36","doi-asserted-by":"publisher","first-page":"11876","DOI":"10.1074\/jbc.M116.723577","volume":"291","author":"KW Anderson","year":"2016","unstructured":"Anderson KW, Mast N, Hudgens V et al (2016) Mapping of the allosteric site in cholesterol hydroxylase CYP46A1 for efavirenz, a drug that stimulates enzyme activity. J Biol Chem 291:11876\u201311886","journal-title":"J Biol Chem"},{"key":"1162_CR37","doi-asserted-by":"publisher","first-page":"9546","DOI":"10.1073\/pnas.0803717105","volume":"105","author":"N Mast","year":"2008","unstructured":"Mast N, White MA, Bjorkhem I et al (2008) Crystal structures of substrate-bound and substrate-free cytochrome P450 46A1, the principal cholesterol hydroxylase in the brain. Proc Natl Acad Sci USA 105:9546\u20139955","journal-title":"Proc Natl Acad Sci USA"},{"key":"1162_CR38","doi-asserted-by":"publisher","first-page":"3529","DOI":"10.1074\/jbc.M113.532846","volume":"289","author":"N Mast","year":"2014","unstructured":"Mast N, Li Y, Linger M, Clark M, Wiseman J, Pikuleva IA (2014) Pharmacologic stimulation of cytochrome P450 46A1 and cerebral cholesterol turnover in mice. J Biol Chem 289:3529\u20133538","journal-title":"J Biol Chem"},{"key":"1162_CR39","doi-asserted-by":"publisher","first-page":"12934","DOI":"10.1074\/jbc.M117.794909","volume":"292","author":"N Mast","year":"2017","unstructured":"Mast N, Anderson KW, Johnson KM et al (2017) In vitro cytochrome P450 46A1 (CYP46A1) activation by neuroactive compounds. J Biol Chem 292:12934\u201312946","journal-title":"J Biol Chem"},{"key":"1162_CR40","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.neuropharm.2017.06.026","volume":"123","author":"N Mast","year":"2017","unstructured":"Mast N, Saadane A, Valencia-Olvera A et al (2017) Cholesterol-metabolizing enzyme cytochrome P450 46A1 as a pharmacologic target for Alzheimer\u2019s disease. Neuropharmacology 123:465\u2013476","journal-title":"Neuropharmacology"},{"key":"1162_CR41","doi-asserted-by":"publisher","first-page":"e10924","DOI":"10.15252\/emmm.201910924","volume":"12","author":"M Han","year":"2020","unstructured":"Han M, Wang S, Yang N et al (2020) Therapeutic implications of altered cholesterol homeostasis mediated by loss of CYP46A1 in human glioblastoma. EMBO Mol Med 12:e10924","journal-title":"EMBO Mol Med"},{"key":"1162_CR42","doi-asserted-by":"publisher","first-page":"41918","DOI":"10.1074\/jbc.M405652200","volume":"279","author":"A Ertmer","year":"2004","unstructured":"Ertmer A, Gilch S, Yun SW et al (2004) The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells. J Biol Chem 279:41918\u201341927","journal-title":"J Biol Chem"},{"key":"1162_CR43","doi-asserted-by":"publisher","first-page":"3957","DOI":"10.1093\/emboj\/20.15.3957","volume":"20","author":"S Gilch","year":"2001","unstructured":"Gilch S, Winklhofer KF, Groschup MH et al (2001) Intracellular re-routing of prion protein prevents propagation of PrPSc and delays onset of prion disease. EMBO J 20:3957\u20133966","journal-title":"EMBO J"},{"key":"1162_CR44","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/0092-8674(93)90275-U","volume":"73","author":"M Scott","year":"1993","unstructured":"Scott M, Groth D, Foster D et al (1993) Propagation of prions with artificial properties in transgenic mice expressing chimeric PrP genes. Cell 73:979\u2013988","journal-title":"Cell"},{"key":"1162_CR45","doi-asserted-by":"publisher","first-page":"20908","DOI":"10.1073\/pnas.0710054104","volume":"104","author":"SP Sukhvir","year":"2007","unstructured":"Sukhvir SP, Baker CA, Demczyk CA, Smith EW, Julius C, Weissmann C (2007) Prion strain discrimination in cell culture: the cell panel assay. Proc Natl Acad Sci USA 104:20908\u201320913","journal-title":"Proc Natl Acad Sci USA"},{"key":"1162_CR46","doi-asserted-by":"publisher","first-page":"e1006553","DOI":"10.1371\/journal.ppat.1006553","volume":"13","author":"S Hannaoui","year":"2017","unstructured":"Hannaoui S, Amidian S, Cheng YC et al (2017) Destabilizing polymorphism in cervid prion protein hydrophobic core determines prion conformation and conversion efficiency. PLoS Pathog 13:e1006553","journal-title":"PLoS Pathog"},{"key":"1162_CR47","doi-asserted-by":"publisher","first-page":"21658","DOI":"10.1038\/srep21658","volume":"11","author":"SY Shim","year":"2016","unstructured":"Shim SY, Karri S, Law S, Schatzl HM, Gilch S (2016) Prion infection impairs lysosomal degradation capacity by interfering with rab7 membrane attachment in neuronal cells. Sci Rep 11:21658. https:\/\/doi.org\/10.1038\/srep21658","journal-title":"Sci Rep"},{"key":"1162_CR48","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1007\/s12035-018-1421-1","volume":"56","author":"A Bartoletti-Stella","year":"2019","unstructured":"Bartoletti-Stella A, Corrado P, Mometto N et al (2019) Analysis of RNA expression profiles identifies dysregulated vesicle trafficking pathways in Creutzfeldt-Jakob disease. Mol Neurobiol 56:5009\u20135024","journal-title":"Mol Neurobiol"},{"key":"1162_CR49","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1016\/S1474-4422(20)30273-8","volume":"19","author":"E Jones","year":"2020","unstructured":"Jones E, Hummerich H, Vir\u00e9 E et al (2020) Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study. Lancet Neurol 19:840\u2013848","journal-title":"Lancet Neurol"},{"key":"1162_CR50","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1146\/annurev.biochem.78.072407.103859","volume":"78","author":"DW Russell","year":"2009","unstructured":"Russell DW, Halford RW, Ramirez DM, Shah R, Kotti T (2009) Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu Rev Biochem 78:1017\u20131040","journal-title":"Annu Rev Biochem"},{"key":"1162_CR51","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1073\/pnas.1917421117","volume":"117","author":"E Yutuc","year":"2020","unstructured":"Yutuc E, Angelini R, Baumert M et al (2020) Localization of sterols and oxysterols in mouse brain reveals distinct spatial cholesterol metabolism. Proc Natl Acad Sci USA 117:5749\u20135760","journal-title":"Proc Natl Acad Sci USA"},{"key":"1162_CR52","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/cne.21605","volume":"507","author":"DM Ramirez","year":"2008","unstructured":"Ramirez DM, Andersson S, Russell DW (2008) Neuronal expression and subcellular localization of cholesterol 24-hydroxylase in the mouse brain. J Comp Neurol 507:1676\u20131693","journal-title":"J Comp Neurol"},{"key":"1162_CR53","first-page":"1911","volume":"1861","author":"M Moutinho","year":"2016","unstructured":"Moutinho M, Nunes MJ, Rodrigues E (2016) Cholesterol 24-hydroxylase: brain cholesterol metabolism and beyond. Biochem Biophys Acta 1861:1911\u20131920","journal-title":"Biochem Biophys Acta"},{"key":"1162_CR54","doi-asserted-by":"publisher","first-page":"3810","DOI":"10.1074\/jbc.M505179200","volume":"281","author":"Y Ohyama","year":"2006","unstructured":"Ohyama Y, Meaney S, Heverin M (2006) Studies on the transcriptional regulation of cholesterol 24-hydroxylase (CYP46A1): marked insensitivity toward different regulatory axes. J Biol Chem 281:3810\u20133820","journal-title":"J Biol Chem"},{"key":"1162_CR55","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1128\/JVI.74.7.3135-3140.2000","volume":"74","author":"A Mang\u00e9","year":"2000","unstructured":"Mang\u00e9 A, Nishida N, Milhavet O, McMahon HE, Casanova D, Lehmann S (2000) Amphotericin B inhibits the generation of the scrapie isoform of the prion protein in infected cultures. J Virol 74:3135\u20133140","journal-title":"J Virol"},{"key":"1162_CR56","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1172\/JCI0216390","volume":"110","author":"K Simons","year":"2002","unstructured":"Simons K, Ehehalt R (2002) Cholesterol, lipid rafts, and disease. J Clin Invest 110:597\u2013603","journal-title":"J Clin Invest"},{"key":"1162_CR57","doi-asserted-by":"publisher","first-page":"fcaa043","DOI":"10.1093\/braincomms\/fcaa043","volume":"20","author":"AM Petrov","year":"2020","unstructured":"Petrov AM, Mast N, Li Y, Denker J, Pikuleva IA (2020) Brain sterol flux mediated by cytochrome P450 46A1 affects membrane properties and membrane-dependent processes. Brain Commun 20:fcaa043","journal-title":"Brain Commun"},{"key":"1162_CR58","unstructured":"Kant RV, Langness VF, Herrera CM et al (2019) Cholesterol metabolism is a druggable axis that independently regulates tau and amyloid-beta in iPSC-derived Alzheimer\u2019s disease neurons. Cell Stem Cell 24: 363\u2013375 e369"},{"key":"1162_CR59","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.ejphar.2017.07.016","volume":"812","author":"N Apostolova","year":"2017","unstructured":"Apostolova N, Blas-Garcia A, Galindo MJ, Esplugues JV (2017) Efavirenz: what is known about the cellular mechanisms responsible for its adverse effects. Eur J Pharmacol 812:163\u2013173","journal-title":"Eur J Pharmacol"},{"key":"1162_CR60","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1055\/s-0033-1359314","volume":"33","author":"LT Takada","year":"2013","unstructured":"Takada LT, Geschwind MD (2013) Prion diseases. Semin Neurol 33:348\u2013356","journal-title":"Semin Neurol"},{"key":"1162_CR61","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1099\/jgv.0.000876","volume":"98","author":"JA Carroll","year":"2017","unstructured":"Carroll JA, Race B, Phillips K, Striebel JF, Chesebro B (2017) Statins are ineffective at reducing neuroinflammation or prolonging survival in scrapie-infected mice. J Gen Virol 98:2190\u20132199","journal-title":"J Gen Virol"}],"container-title":["Acta Neuropathologica Communications"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-021-01162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40478-021-01162-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40478-021-01162-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T12:24:42Z","timestamp":1617279882000},"score":1,"resource":{"primary":{"URL":"https:\/\/actaneurocomms.biomedcentral.com\/articles\/10.1186\/s40478-021-01162-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1162"],"URL":"https:\/\/doi.org\/10.1186\/s40478-021-01162-1","relation":{},"ISSN":["2051-5960"],"issn-type":[{"value":"2051-5960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"15 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing financial interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}